Serum Copper: A Biomarker for Alzheimer Disease?

Archives of Neurology

Volumn 61, Issue 5, 2004, Pages 631-632

  Bush, Ashley I ^a   Strozyk, Dorothea ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CLIOQUINOL; COPPER; CYTOCHROME; HYDROGEN PEROXIDE; ISOPROTEIN; ZINC;

ALZHEIMER DISEASE; BRAIN MITOCHONDRION; BRAIN TISSUE; CHELATION; DIAGNOSTIC VALUE; DISEASE MARKER; EDITORIAL; GENETIC MARKER; HUMAN; NEUROPATHOLOGY; OXIDATION REDUCTION REACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY CHAIN;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BIOLOGICAL MARKERS; BRAIN; COPPER; HUMANS;

EID: 2442420176     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.5.631     Document Type: Editorial

References (13)

1. Opazo C, Huang X, Cherny R, et al. Metalloenzyme-like activity of Alzheimer's disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2. J Biol Chem. 2002;277:40302-40308.
2. Maynard CJ, Cappal R, Volitakis I, et al. Overexpression of Alzheimer's disease p-amyloid opposes the age-dependent elevations of brain copper and iron levels. J Biol Chem. 2002;277:44670-44676.
3. Bush AI. The metallobiology of Alzheimers disease. Trends Neurosci. 2003;26:207-214.
4. Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer's p-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003;278:42959-42965.
5. Squitti R, Cassetta E, Dal Forno G, et al. Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment. Arch Neurol. 2004;61:738-743.
6. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology. 2002;59:1153-1161.
7. Squitti R, Pasqualetti P, Cassetta E, et al. Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology. 2003;60:2013-2014.
8. Barceloux DG, Copper. J Toxicol Clin Toxicol. 1999;37:217-230.
9. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amylold β-protein, and the β-amyloid precursor protein Intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162-4167.
10. Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100:11065-11069.
11. Chemy RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665-676.
12. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685-1691.
13. Schiefermeier M, Kollegger H, Madl C, et al. The impact of apolipoprotein E geno-types on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain. 2000;123:585-590.